medigraphic.com
ISSN 1561-302X (Print)

2018, Number 2

<< Back Next >>

Rev cubana med 2018; 57 (2)

Disease by cytomegalovirus in renal transplants

Cruz ARE, Véliz GM, Hernández FME, González CY, Hernández POA

Language: Spanish
References: 27
Page: 1-11
PDF size: 193.73 Kb.


ABSTRACT

Introduction: The disease by cytomegalovirus in the renal transplant represents a threat for the survival of the graft and of the patient.
Objective: To characterize the morbidity and mortality of the disease by cytomegalovirus in recipients of renal transplant.
Methods: A prospective, descriptive and observational study was carried out in "Arnaldo Milián Castro" Provincial Clinical- Surgical University Hospital between 2014 and 2016 that included 49 patients. Socio-demographic variables, ethiology of the original nephropathy, form of presentation of the disease, comorbidity, immunosuppressive guidelines used, the response to ganciclovir and the condition of the patient in the moment of discharge were chosen, as well as the causes of death.
Results: The average age was 46,55 (±13,02 years) with predominance of the masculine sex (relation 2:1) (p=0,727). The unspecific form and the moment of late appearance was a majority (81, 63 %) (p=0,498). The preponderant comorbility was the infection of the urinary tract. The immunosuppressive guideline of prednisone-mycophenolate mofetil was used in 26 patients (53, 06 %); 33 patients (67,35 %) responded adequately to ganciclovir (p=0,907) and the third part (26,53 %) of the patients died due to acute respiratory failure (p=0,447).
Conclusions: The disease by cytomegalovirus constitutes a real threat in inmunocompromised patients.


REFERENCES

  1. García-García G, Harden P, Chapman J. El papel global del trasplante renal. Nefrología. 2012;32(1):1-6.

  2. Martínez-Castelao A, Górriz JL, Bover J, Segura-de la Morena J, Cebollada J, Escalada J, et al. Documento de consenso para la detección y manejo de la enfermedad renal crónica. Nefrología. Madrid; 2014;34(2):243-62.

  3. Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;(Suppl 3):6-308.

  4. Gómez J, Gabilondo B, Alessio LP, Manzano MC, Bordes J. Trasplante renal: Epidemiología y características clínicas en cinco años. Rev Invest Med Sur Mex. 2013;20(4):214-6.

  5. Berli JU, Montgomery JR, Segev DL, Ratner LE, Maley WR, Cooper M, et al. Surgical management of early and late ureteral complications after renal transplantation: techniques and outcomes. Clinical Transplantation. 2015;29(1):26-33.

  6. Sousa SR, Galante NZ, Barbosa DA, Pestana JO. Incidence of infectious complications and their risk factors in the first year after renal transplantation. J Bras Nefrol. 2010;32(1):75-82.

  7. Witzke O, Hauser IA, Bartels M, Wolf G, Wolters H, Nitschke M, VIPP Study Group. Valganciclovir prophylaxis versus preemptive therapy in cytomegaloviruspositive renal allograft recipients: 1-year results of a randomized clinical trial. Transplantation. 2012;93(1):61-8.

  8. Manuel O, Husain S, Kumar D, Zayas C, Mawhorter S, Levi ME, et al. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis. 2013;56(6):817-24.

  9. Koton CN. CMV: Prevention, diagnosis and therapy. Am J Transplant. 2013;13(Suppl 3):24-40.

  10. Pérez A, Morales LE, Vilatobá M. Factores de riesgo para el desarrollo de función retardada del injerto en receptores de trasplante renal de donante fallecido y su impacto en la supervivencia de paciente e injerto. Revista de Investigación Clínica. 2013;65(2):109-15.

  11. López-Oliva MO, Flores J, Madero R, Escuin F, Santana MJ, Bellón T, et al. Cytomegalovirus infection after kidney transplantation and long-term graft loss. Nefrología. 2017;37(5):515-25.

  12. Valdivia J, Gutiérrez C, Delgado E. Supervivencia en el trasplante renal con donante vivo y donante fallecido. Invest Médico Quir. 2011;3(2):99-107.

  13. Hernández D, Triñanes J, Armas AM, Ruiz-Esteban P, Alonso-Titos J, Duarte A, et al. Vascular damage and kidney transplant outcomes: An unfriendly and harmful link. Am J Med Sci. 2017;354(1):7-16.

  14. Ávila-Saldívar MN. Enfermedad renal crónica: prevención y detección temprana en el primer nivel de atención. Med Int Mex. 2013;29:148-53.

  15. De Francisco LM. Insuficiencia renal crónica: alternativas terapéuticas. En: Arias M, Campistol JM, Morales JM. Manual de trasplante renal. 1 ed. Madrid: Grupo 2 Comunicación Médica; 2005. p. 11-25.

  16. Silva M, Marra AR, Pereira CA, Medina JO, Camargo LF. Bloodstream infection after kidney transplantation: epidemiology, microbiology, associated risk factors, and outcome. Transplantation. 2011;90:581-7.

  17. Razonable RR, Humar A. Cytomegalovirus in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):93-106.

  18. Sanbonmatsu S, Pérez M, Navarro JM. Infección por citomegalovirus humano. Enferm Infecc Microbiol Clin. 2014;32(Supl 1):15-22.

  19. Cortés JA, Yomayusa N, Arias YR, Arroyave IH, Cataño JC, García P, et al. Consenso colombiano para la estratificación, diagnóstico, tratamiento y prevención de la infección por citomegalovirus en pacientes adultos con trasplante renal. Infectio. 2016;20(4):250-64.

  20. Días J, Henao JE, Jaimes FA. Efectos de la infección y la enfermedad por citomegalovirus en receptores de trasplante renal. Acta Med Colom. 2012;37:131-7.

  21. Kosmadakis G, Daikos GL, Pavlopoulou ID, Gobou A, Kostakis A, Tzanatou- Exarchou H, et al. Infectious complications in the first year post renal transplantation. Transplant Proc. 2013;45(4):1579-83.

  22. Batista MV, Pierrotti LC, Abdala E, Clemente WT, Girão ES, Rosa DR, et al. Endemic and opportunistic infections in Brazilian solid organ transplant recipients. Trop Med Int Health. 2011;16(9):1134-42.

  23. Ahmed A. Antiviral treatment of cytomegalovirus infection. Infect Disord Drug Targets. 2011;11(5):475-503.

  24. Díaz J, Henao J, Rodelo J, García A, Arbelaez M, Jaimes F. Incidence and risk factors for cytomegalovirus disease in a Colombian cohort of kidney transplant recipients. Trasplant Proc. 2014;46:160-6.

  25. I ak O, Yildirim M, Kucuk HF, Gencer S, Demir T. Infections in renal transplant patients: risk factors and infectious agents. Transplant Proc. 2013;45(3):944-8.

  26. Hodson EM, Ladhani M, Webster A, Strippoli GF, Craig J. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database of Systematic Rev. 2013;28(2):CD003774.

  27. Owers DS, Webster AC, Strippoli GF, Kable K, Hodson EM. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients (Review) Cochrane Database of Systematic Rev. 2013;28(2):CD005133.




2020     |     www.medigraphic.com